Response_NN
to_TO
intranasal_JJ
fluticasone_NN
propionate_NN
in_IN
perennial_JJ
allergic_JJ
rhinitis_NN
not_RB
associated_VBN
with_IN
glucocorticoid_NN
receptor_NN
characteristics_NNS
._.

BACKGROUND_NN
:_:
The_DT
reduction_NN
of_IN
symptoms_NNS
due_JJ
to_TO
treatment_NN
with_IN
corticosteroids_NNS
varies_VBZ
among_IN
patients_NNS
with_IN
perennial_JJ
rhinitis_NN
._.

Most_JJS
patients_NNS
will_MD
respond_VB
but_CC
a_DT
few_JJ
patients_NNS
respond_VBP
less_JJR
to_TO
these_DT
drugs_NNS
._.

OBJECTIVE_NN
:_:
To_TO
investigate_VB
the_DT
association_NN
in_IN
reduction_NN
of_IN
symptoms_NNS
due_JJ
to_TO
glucocorticoids_NNS
and_CC
glucocorticoid_NN
receptor_NN
characteristics_NNS
in_IN
patients_NNS
with_IN
perennial_JJ
allergic_JJ
rhinitis_NN
,_,
in_FW
vitro_FW
glucocorticoid_NN
receptor_NN
binding_NN
studies_NNS
were_VBD
performed_VBN
with_IN
peripheral_JJ
blood_NN
mononuclear_JJ
cells_NNS
using_VBG
dexamethasone_NN
and_CC
in_FW
vitro_FW
production_NN
of_IN
mediators_NNS
were_VBD
measured_VBN
._.

METHODS_NNS
:_:
During_IN
a_DT
double-blind_JJ
placebo-controlled_JJ
crossover_JJ
study_NN
,_,
200_CD
micrograms_NNS
fluticasone_NN
propionate_NN
aqueous_JJ
nasal_JJ
spray_NN
-LRB-_-LRB-
in_IN
the_DT
active_JJ
treatment_NN
period_NN
-RRB-_-RRB-
and_CC
placebo_NN
-LRB-_-LRB-
in_IN
the_DT
placebo_NN
treatment_NN
period_NN
-RRB-_-RRB-
were_VBD
administered_VBN
twice_RB
daily_RB
for_IN
2_CD
weeks_NNS
to_TO
22_CD
patients_NNS
allergic_JJ
to_TO
house_NN
dust_NN
mite_NN
._.

At_IN
the_DT
end_NN
of_IN
both_DT
treatment_NN
periods_NNS
symptoms_NNS
were_VBD
scored_VBN
after_IN
allergen_NN
provocation_NN
-LRB-_-LRB-
100_CD
,_,
1000_CD
,_,
10000_CD
BU\/mL_NN
-RRB-_-RRB-
and_CC
during_IN
the_DT
9.5_CD
hours_NNS
after_IN
this_DT
challenge_NN
._.

Receptor_NN
binding_NN
studies_NNS
with_IN
dexamethasone_NN
were_VBD
performed_VBN
with_IN
peripheral_JJ
blood_NN
mononuclear_JJ
cells_NNS
._.

Leukotriene_NN
B4_NN
produced_VBN
by_IN
monocytes_NNS
in_FW
vitro_FW
and_CC
soluble_JJ
interleukin-2_NN
receptor_NN
released_VBN
by_IN
lymphocytes_NNS
in_FW
vitro_FW
and_CC
cortisol_NN
levels_NNS
in_IN
plasma_NN
were_VBD
determined_VBN
._.

RESULTS_NNS
:_:
No_DT
significant_JJ
partial_JJ
correlations_NNS
of_IN
the_DT
number_NN
of_IN
the_DT
peripheral_JJ
blood_NN
mononuclear_JJ
cell_NN
glucocorticoid_NN
receptors_NNS
-LRB-_-LRB-
6821_CD
+_CC
\/_JJ
-_:
5669_CD
binding_NN
sites_NNS
per_IN
cell_NN
-RRB-_-RRB-
and_CC
the_DT
affinity_NN
-LRB-_-LRB-
Kd_NN
:_:
16.5_CD
+_CC
\/_CD
-_:
13.51_CD
nmol\/L_NN
-RRB-_-RRB-
for_IN
the_DT
glucocorticoid_NN
receptors_NNS
with_IN
the_DT
symptom_NN
score_NN
-LRB-_-LRB-
placebo_NN
:_:
4.3_CD
+_CC
\/_CD
-_:
2.45_CD
pts_NNS
;_:
fluticasone_NN
:_:
2.4_CD
+_CC
\/_CD
-_:
1.55_CD
pts_NNS
-RRB-_-RRB-
after_IN
active_JJ
treatment_NN
were_VBD
found_VBN
._.

Also_RB
no_DT
significant_JJ
partial_JJ
correlations_NNS
of_IN
the_DT
levels_NNS
of_IN
leukotriene_NN
B4_NN
-LRB-_-LRB-
45.6_JJ
+_CC
\/_JJ
-_CC
105.3_CD
ng\/10_NN
6_CD
cells_NNS
-RRB-_-RRB-
produced_VBN
by_IN
monocytes_NNS
in_FW
vitro_FW
,_,
soluble_JJ
interleukin-2_NN
receptor_NN
-LRB-_-LRB-
734_JJ
+_CC
\/_JJ
-_CC
237_CD
ng\/10_NN
6_CD
cells_NNS
-RRB-_-RRB-
released_VBN
by_IN
lymphocytes_NNS
in_FW
vitro_FW
and_CC
cortisol_NN
levels_NNS
-LRB-_-LRB-
571_CD
+_CC
\/_CD
-_:
236_CD
ng\/mL_NN
-RRB-_-RRB-
in_IN
plasma_NN
with_IN
the_DT
symptom_NN
score_NN
after_IN
active_JJ
treatment_NN
were_VBD
found_VBN
._.

CONCLUSIONS_NNS
:_:
The_DT
reduction_NN
of_IN
symptoms_NNS
due_JJ
to_TO
topical_JJ
fluticasone_NN
propionate_NN
in_IN
patients_NNS
with_IN
rhinitis_NN
and_CC
allergy_NN
to_TO
house_NN
dust_NN
mite_NN
is_VBZ
not_RB
correlated_VBN
with_IN
the_DT
characteristics_NNS
of_IN
the_DT
glucocorticoid_NN
receptor_NN
._.

